(Q95177432)

https://api.crossref.org/v1/works/http://dx.doi.org/10.1016/S0140-6736(20)31180-6

23 May 2020

retracted paper

2 references

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

title

Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis (English)

1 reference

https://api.crossref.org/v1/works/http://dx.doi.org/10.1016/S0140-6736(20)31180-6

23 May 2020

0 references

0 references

0 references

3

Frank Ruschitzka

1 reference

https://api.crossref.org/v1/works/http://dx.doi.org/10.1016/S0140-6736(20)31180-6

23 May 2020

Sapan S Desai

series ordinal

2

0 references

Amit Patel

series ordinal

4

object named as

Amit N Patel

0 references

Mandeep R. Mehra

series ordinal

1

0 references

language of work or name

English

0 references

publication date

22 May 2020

1 reference

https://api.crossref.org/v1/works/http://dx.doi.org/10.1016/S0140-6736(20)31180-6

23 May 2020

significant event

expression of concern

point in time

3 June 2020

1 reference

Expression of concern: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

2 references

https://api.crossref.org/v1/works/http://dx.doi.org/10.1016/S0140-6736(20)31180-6

23 May 2020

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32450107%20AND%20SRC:MED&resulttype=core&format=json

Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

30 May 2020

is retracted by

0 references

cites work

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7255293

Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells.

10 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7255293

Endothelial cell infection and endotheliitis in COVID-19

10 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7255293

COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal

10 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7255293

Activity of azithromycin or erythromycin in combination with antimalarial drugs against multidrug-resistant Plasmodium falciparum in vitro

10 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7255293

Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: A randomized controlled trial.

10 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7255293

Management of cardiovascular diseases in patients with obesity

10 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7255293

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

10 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7255293

Azithromycin and the risk of cardiovascular death

10 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7255293

Chloroquine or hydroxychloroquine for prophylaxis of COVID-19

10 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7255293

The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19

10 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7255293

New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?

10 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7255293

Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial

10 February 2021

0 references

Hydroxychloroquine and azithromycin as a treatment of COVID‐19: results of an open‐label non‐randomized clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7255293

Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19)

10 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7255293

Possible Consequences of a Shortage of Hydroxychloroquine for Lupus Patients Amid the COVID-19 Pandemic

10 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7255293

Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19

10 February 2021

0 references

No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial

0 references

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7255293

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)

10 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7255293

Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality

10 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7255293

Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19

10 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7255293

Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)

10 February 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2820%2931180-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Obesity and Outcomes in COVID-19: When an Epidemic and Pandemic Collide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7255293

Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19

10 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7255293

[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19]

10 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7255293

Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial

10 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7255293

Retraction: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2007621

10 February 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2820%2931180-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

2 references

https://api.crossref.org/v1/works/http://dx.doi.org/10.1016/S0140-6736(20)31180-6

23 May 2020

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32450107%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

0 references

0 references

1 reference

Europe PubMed Central